Asset
SETMELANOTIDE
RHYTHM PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04348175 | phase1 | completed | 2020-07-09 | 2021-04-17 | Rhythm Pharmaceuticals, Inc. | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment |
| NCT06772597 | phase2 | active_not_recruiting | 2025-03-04 | 2026-10-31 | Rhythm Pharmaceuticals, Inc. | A Study of Setmelanotide in Patients With Prader-Willi Syndrome |
| NCT05774756 | phase3 | active_not_recruiting | 2023-04-26 | 2025-03-18 | Rhythm Pharmaceuticals, Inc. | A Trial of Setmelanotide in Acquired Hypothalamic Obesity |
| NCT06760546 | phase3 | recruiting | 2025-09-23 | 2027-03-13 | Rhythm Pharmaceuticals, Inc. | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) |
| NCT04963231 | phase2 | completed | 2021-11-30 | 2023-08-04 | Rhythm Pharmaceuticals, Inc. | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway |
FDA applications (0)
This company has no applications containing this asset.